NUH ENDOCRINOLOGY TEAM SHOWCASES END-TO-END CARE MODEL THAT PROTECTS HOSPITALISED PATIENTS WITH DIABETES MELLITUS (DM) ACROSS THEIR CARE JOURNEY

NUH ENDOCRINOLOGY TEAM SHOWCASES END-TO-END CARE MODEL THAT PROTECTS HOSPITALISED PATIENTS WITH DIABETES MELLITUS (DM) ACROSS THEIR CARE JOURNEY

NUH's Inpatient DM management team highlights how safe prescribing is strengthened through proactive monitoring, rapid intervention and coordinated care transitions. SINGAPORE, Sept. 21, 2026 /PRNewswire/ -- Newer diabetes treatments are...

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 26, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's...

menu
menu